Belotecan

Drug Profile

Belotecan

Alternative Names: Belotecan hydrochloride; Camtobell; CKD 602; EQ-917; S-CKD602

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Chonnam National University Hospital; OnKor Pharmaceuticals
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • No development reported Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Aug 2015 Phase-IIb development for Ovarian cancer (Late-stage disease) is ongoing in South Korea (NCT01630018)
  • 13 Aug 2015 No recent reports on development identified - Phase-I for Solid tumours in South Korea (PO)
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top